Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436555 | 0.92 | ADORA2A (0.46) | ADORA2AADORA2BADORA1LRRK2 | |
| SCHEMBL20416648 | 0.92 | ADORA2A (0.46) | ADORA2AADORA2BADORA1LRRK2 | |
| SCHEMBL20436568 | 0.92 | ADORA2A (0.45) | HRH4HTR1AADRA2AADRA2CHTR1D | |
| SCHEMBL20436556 | 0.91 | ADORA2A (0.46) | ADORA2AADORA2BADORA1LRRK2 | |
| SCHEMBL20416782 | 0.91 | HRH4 (0.48) | HRH4HRH3ADORA2AADORA2BADORA1 | |
| SCHEMBL20436565 | 0.90 | ADORA2A (0.45) | ADORA2AADORA2BADORA1LRRK2 | |
| SCHEMBL20436554 | 0.88 | ADORA2A (0.46) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20436571 | 0.87 | ADORA2A (0.43) | HRH4HTR1AADRA2AADRA2CHTR1D | |
| SCHEMBL20436570 | 0.87 | ADORA2A (0.43) | HRH4HTR1AADRA2AADRA2CHTR1D | |
| SCHEMBL30402277 | 0.87 | ADORA2A (0.43) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | HRH4 787/4885HTR1A 590/4885ADRA2A 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.